Biological activity of analogues of YM022. Novel (3-amino substituted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antagonists

Chemical and Pharmaceutical Bulletin

Volumn 44, Issue 7, 1996, Pages 1412-1414

  Satoh, Masato ^a   Okamoto, Yoshinori ^a   Koshio, Hiroyuki ^a   Ohta, Mitsuaki ^a   Nishida, Akito ^a   Akuzawa, Shinobu ^a   Miyata, Keiji ^a   Mase, Toshiyasu ^a   Semple, Graeme ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b Chilworth Research Centre   (United Kingdom)

Author keywords

1,4 benzodiazepin 2 one; gastrin CCK B receptor antagonist; pentagastrin induced gastric acid secretion; structure activity relationship; YM022

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; BENZODIAZEPIN 2 ONE DERIVATIVE; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; GASTRIN ANTAGONIST; PENTAGASTRIN; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; INTRADUODENAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RAT; RECEPTOR BLOCKING; STOMACH ACID SECRETION; STRUCTURE ACTIVITY RELATION;

EID: 0030036247     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.44.1412     Document Type: Article

References (13)

1. Satoh M., Kondoh Y., Okamoto Y., Nishida A., Miyata K., Ohta M., Mase T., Murase K., Chem. Pharm. Bull., 43, 2159-2167 (1995).
2. a) Bock M. G., DiPardo R. M., Evans B. E., Rittle K. E., Whitter W. L., Veber D. F., Anderson P. S., Freidinger R. M., J. Med. Chem., 32, 13-16 (1989)
3. b) Lotti V. J., Chang R. S. L., Eur. J. Pharmacol., 162, 273-280 (1989).
4. a) Bock M. G., DiPardo R. M., Evans B. E., Rittle K. E., Whitter W. L., Garsky V. M., Gilbert K. F., Leighton J. L., Carson K. L., Mellin E. C., Veber D. F., Chang R. S. L., Lotti V. J., Freedman S. B., Smith A. J., Patel S., Anderson P. S., Freidinger R. M., J. Med. Chem., 36, 4276-4292 (1993)
5. b) Showell G. A., Bourrain S., Neduvelil J. G., Fletcher S. R., Baker R., Watt A. P., Fletcher A. E., Freedman S. B., Kemp J. A., Marshall G. R., Patel S., Smith A. J., Matassa V. G., ibid., 37, 719-721 (1994)
6. c) Bock M. G., DiPardo R. M., Mellin E. C., Newton R. C., Veber D. F., Freedman S. B., Smith A. J., Patel S., Kemp J. A., Marshall G. R., Fletcher A. E., Chapman K. L., Anderson P. S., Freidinger R. M., ibid., 37, 722-724 (1994).
7. Nishida A., Yuki H., Tsutsumi R., Miyata K., Kamato T., Ito H., Yamano M., Honda K., Jpn. J. Pharmacol., 58, 137-145 (1992);
8. Semple G., Ryder H., Kendrick D. A., Szelke M., Ohta M., Satoh M., Nishida A., Akuzawa S., Miyata K., Bioorg. Med. Chem. Lett., 6, 51-54 (1996).
9. Semple G., Ryder H., Kendrick D. A., Szelke M . Ohta M., Satoh M., Nishida A., Akuzawa S., Miyata K., Bioorg. Med. Chem. Lett., 6, 55-58 (1996).
10. Chang R. S. L., Lotti V. J., Proc. Natl. Acad. Sci. U.S.A., 83, 4923-4926 (1986).
11. Chang R. S. L., Lotti V. J., Chen T. B., Kunkel K. A., Mol. Pharmacol., 30, 212-217 (1986).
12. Takeuchi K., Furukawa O., Tanaka H., Okabe S., Gastroenterology, 90, 636-645 (1986).
13. Semple G., Ryder H., Szelke M., Satoh M., Ohta M., Miyata K., Nishida A., Ishii, M., PCT Int. Appl., WO 95/06040 (1995).